Literature DB >> 26908254

Structural characterization of ANGPTL8 (betatrophin) with its interacting partner lipoprotein lipase.

Amnah Siddiqa1, Jamil Ahmad2, Amjad Ali3, Rehan Zafar Paracha3, Zurah Bibi1, Babar Aslam3.   

Abstract

Angiopoietin-like protein 8 (ANGPTL8) (also known as betatrophin) is a newly identified secretory protein with a potential role in autophagy, lipid metabolism and pancreatic beta-cell proliferation. Its structural characterization is required to enhance our current understanding of its mechanism of action which could help in identifying its receptor and/or other binding partners. Based on the physiological significance and necessity of exploring structural features of ANGPTL8, the present study is conducted with a specific aim to model the structure of ANGPTL8 and study its possible interactions with Lipoprotein Lipase (LPL). To the best of our knowledge, this is the first attempt to predict 3-dimensional (3D) structure of ANGPTL8. Three different approaches were used for modeling of ANGPTL8 including homology modeling, de-novo structure prediction and their amalgam which is then proceeded by structure verification using ERRATT, PROSA, Qmean and Ramachandran plot scores. The selected models of ANGPTL8 were further evaluated for protein-protein interaction (PPI) analysis with LPL using CPORT and HADDOCK server. Our results have shown that the crystal structure of iSH2 domain of Phosphatidylinositol 3-kinase (PI3K) p85β subunit (PDB entry: 3mtt) is a good candidate for homology modeling of ANGPTL8. Analysis of inter-molecular interactions between the structure of ANGPTL8 and LPL revealed existence of several non-covalent interactions. The residues of LPL involved in these interactions belong from its lid region, thrombospondin (TSP) region and heparin binding site which is suggestive of a possible role of ANGPTL8 in regulating the proteolysis, motility and localization of LPL. Besides, the conserved residues of SE1 region of ANGPTL8 formed interactions with the residues around the hinge region of LPL. Overall, our results support a model of inhibition of LPL by ANGPTL8 through the steric block of its catalytic site which will be further explored using wet lab studies in future.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ANGPTL8; Betatrophin; Comparative modeling; LPL; Protein structure

Mesh:

Substances:

Year:  2016        PMID: 26908254     DOI: 10.1016/j.compbiolchem.2016.01.009

Source DB:  PubMed          Journal:  Comput Biol Chem        ISSN: 1476-9271            Impact factor:   2.877


  10 in total

1.  Angiopoietin-like proteins as therapeutic targets for cardiovascular disease: focus on lipid disorders.

Authors:  Marco Bruno Morelli; Christopher Chavez; Gaetano Santulli
Journal:  Expert Opin Ther Targets       Date:  2020-01-15       Impact factor: 6.902

2.  Histology and molecular biology studies on the expression and localization of angiopoietin-like protein 8 in human tissues.

Authors:  Naohiko Akimoto; Ryuichi Wada; Katsuhiko Iwakiri; Zenya Naito
Journal:  Biomed Rep       Date:  2019-09-25

3.  ANGPTL8 requires ANGPTL3 to inhibit lipoprotein lipase and plasma triglyceride clearance.

Authors:  Jorge F Haller; Ivory J Mintah; Lisa M Shihanian; Panayiotis Stevis; David Buckler; Corey A Alexa-Braun; Sandra Kleiner; Serena Banfi; Jonathan C Cohen; Helen H Hobbs; George D Yancopoulos; Andrew J Murphy; Viktoria Gusarova; Jesper Gromada
Journal:  J Lipid Res       Date:  2017-04-15       Impact factor: 5.922

4.  On the mechanism of angiopoietin-like protein 8 for control of lipoprotein lipase activity.

Authors:  Oleg Kovrov; Kristian Kølby Kristensen; Erika Larsson; Michael Ploug; Gunilla Olivecrona
Journal:  J Lipid Res       Date:  2019-01-27       Impact factor: 5.922

5.  Downregulated angiopoietin-like protein 8 production at calving related to changes in lipid metabolism in dairy cows.

Authors:  Misato Nakano; Yutaka Suzuki; Satoshi Haga; Eri Yamauchi; Dahye Kim; Koki Nishihara; Keiichi Nakajima; Takafumi Gotoh; Seungju Park; Myunggi Baik; Kazuo Katoh; Sanggun Roh
Journal:  J Anim Sci       Date:  2018-06-29       Impact factor: 3.159

6.  Vitamin D modifies the associations between circulating betatrophin and cardiometabolic risk factors among youths at risk for metabolic syndrome.

Authors:  Junling Fu; Cong Hou; Lujiao Li; Dan Feng; Ge Li; Mingyao Li; Changhong Li; Shan Gao; Ming Li
Journal:  Cardiovasc Diabetol       Date:  2016-10-06       Impact factor: 9.951

7.  ANGPTL8 negatively regulates NF-κB activation by facilitating selective autophagic degradation of IKKγ.

Authors:  Yu Zhang; Xian Guo; Wanyao Yan; Yan Chen; Mengxiang Ke; Cheng Cheng; Xiuqin Zhu; Weili Xue; Qiaoqiao Zhou; Ling Zheng; Shun Wang; Bin Wu; Xinran Liu; Liang Ma; Lianqi Huang; Kun Huang
Journal:  Nat Commun       Date:  2017-12-18       Impact factor: 14.919

8.  Angiopoietin-like protein 8 expression and association with extracellular matrix metabolism and inflammation during intervertebral disc degeneration.

Authors:  Zhiwei Liao; Xinghuo Wu; Yu Song; Rongjin Luo; Huipeng Yin; Shengfeng Zhan; Shuai Li; Kun Wang; Yukun Zhang; Cao Yang
Journal:  J Cell Mol Med       Date:  2019-06-18       Impact factor: 5.310

9.  An anti-ANGPTL3/8 antibody decreases circulating triglycerides by binding to a LPL-inhibitory leucine zipper-like motif.

Authors:  Deepa Balasubramaniam; Oliver Schroeder; Anna M Russell; Jonathan R Fitchett; Aaron K Austin; Thomas P Beyer; Yan Q Chen; Jonathan W Day; Mariam Ehsani; Aik Roy Heng; Eugene Y Zhen; Julian Davies; Wolfgang Glaesner; Bryan E Jones; Robert W Siegel; Yue-Wei Qian; Robert J Konrad
Journal:  J Lipid Res       Date:  2022-03-17       Impact factor: 6.676

10.  Angiopoietin-like protein 8 differentially regulates ANGPTL3 and ANGPTL4 during postprandial partitioning of fatty acids.

Authors:  Yan Q Chen; Thomas G Pottanat; Robert W Siegel; Mariam Ehsani; Yue-Wei Qian; Eugene Y Zhen; Ajit Regmi; William C Roell; Haihong Guo; M Jane Luo; Ruth E Gimeno; Ferdinand Van't Hooft; Robert J Konrad
Journal:  J Lipid Res       Date:  2020-06-02       Impact factor: 5.922

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.